09:46 AM EST - Valeant Pharmaceuticals International, Inc. : and Bausch + Lomb Holdings Incorporated, the global eye health company, today announced that they have entered into a definitive agreement under which Valeant will acquire Bausch + Lomb for $8.7 billion in cash. Valeant Pharmaceuticals International, Inc.
shares T.VRX are trading up $7.98 at $95.00.
